Pharmafile Logo
Pharmafocus logo
Advanced Search

CETP inhibitor

Showing 3 posts of 3 posts found.

Roche image

Roche abandons Phase III cholesterol drug

May 8, 2012
Medical Communications, Research and Development, Sales and Marketing CETP inhibitor, Roche, cardiovascular, dalcetrapib, phase III failure

Roche has abandoned its Phase III cholesterol treatment dalcetrapib after disappointing results.The manufacturer is ceasing work on the drug, once …

News

BMS in cholesterol alliance with China’s Simcere

December 16, 2011
Sales and Marketing BMS, CETP inhibitor, Simcere, cardiovascular, emerging markets

Bristol-Myers Squibb is to co-develop a new compound to treat cardiovascular disease with Chinese firm Simcere Pharmaceutical Group. The companies, …

News
Merck

Merck highlights updated pipeline

November 11, 2011
Sales and Marketing CETP inhibitor, Merck, cholesterol, pipeline

Merck has showcased its most promising drug candidates, and says it expects to make eight US filings in the next …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026